Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noa Lavi

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Scientific Reports|May 16, 2022
Socioecology shapes child and adolescent time allocation in twelve hunter-gatherer and mixed-subsistence forager societiesSheina Lew-Levy, Rachel Reckin, Stephen M Kissler, et al.
European Journal of Haematology|February 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS OnsetHazim Khatib, Amit Parizat, Jabour Halloun, et al.
Blood Advances|August 27, 2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, et al.
Nature Medicine|February 23, 2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingYael C Cohen, Mor Zada, Shuang-Yin Wang, et al.
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
American Journal of Hematology|February 13, 2020
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working groupEirini Katodritou, Efstathios Kastritis, Moshe Gatt, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
American Journal of Hematology|November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 casesEmanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Scientific Reports|May 16, 2022
Socioecology shapes child and adolescent time allocation in twelve hunter-gatherer and mixed-subsistence forager societiesSheina Lew-Levy, Rachel Reckin, Stephen M Kissler, et al.
European Journal of Haematology|February 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS OnsetHazim Khatib, Amit Parizat, Jabour Halloun, et al.
Blood Advances|August 27, 2025
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1Carolina Schinke, Paula Rodriguez-Otero, Niels W C J van de Donk, et al.
Nature Medicine|February 23, 2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingYael C Cohen, Mor Zada, Shuang-Yin Wang, et al.
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
American Journal of Hematology|February 13, 2020
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working groupEirini Katodritou, Efstathios Kastritis, Moshe Gatt, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
American Journal of Hematology|November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 casesEmanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
Pageof 6